JY
TCRX icon

Jeff Yass’s TScan Therapeutics TCRX Stock Holding History

Jeff Yass’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2K Sell
23,623
-133,605
-85% -$142K ﹤0.01% 13013
2026
Q1 		$159K Sell
157,228
-58,905
-27% -$62.9K ﹤0.01% 11940
2025
Q4 		$216K Buy
216,133
+136,373
+171% +$197K ﹤0.01% 10714
2025
Q3 		$145K Sell
79,760
-64,612
-45% -$114K ﹤0.01% 11306
2025
Q2 		$209K Buy
144,372
+95,769
+197% +$138K ﹤0.01% 11118
2025
Q1 		$67.1K Buy
48,603
+22,768
+88% +$49.2K ﹤0.01% 11758
2024
Q4 		$78.5K Buy
25,835
+15,659
+154% +$71K ﹤0.01% 11476
2024
Q3 		$50.7K Buy
+10,176
New +$61.4K ﹤0.01% 11371
2024
Q2 		– Sell
-297,902
Closed -$2.37M – 13219
2024
Q1 		$2.37M Buy
297,902
+193,954
+187% +$1.22M ﹤0.01% 4969
2023
Q4 		$606K Buy
103,948
+87,033
+515% +$398K ﹤0.01% 8189
2023
Q3 		$43.3K Buy
+16,915
New +$39.5K ﹤0.01% 11360

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Jeff Yass's TCRX Position: Q2 2026 in Review

Jeff Yass reduced its TScan Therapeutics (TCRX) stake by 85% in Q2 2026, selling an estimated $142K and leaving 23,623 shares worth $23.2K. The position accounts for ﹤0.01% of the portfolio, ranked #13013.

Jeff Yass first reported a position in TCRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.37M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Jeff Yass held 23,623 shares of TScan Therapeutics worth $23.2K as of Q2 2026.
  • Jeff Yass sold 133,605 TScan Therapeutics shares in Q2 2026, an estimated $142K.
  • TScan Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13013 holding.
  • Jeff Yass first reported a position in TScan Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Jeff Yass's TScan Therapeutics position peaked at $2.37M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.